eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Head & Neck Surgery

Buccal Carcinoma

Author: Christopher Klem, MD, Consulting Staff, Department of Otolaryngology-Head and Neck Surgery, Tripler Army Medical Center
Coauthor(s): David P Goldstein, MD, FRCSC, Consulting Staff, Department of Otolaryngology, Division of Head and Neck Oncology and Microvascular Reconstructive Surgery, University Health Network, Toronto; Gerry F Funk, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Iowa; Russell B Smith, MD, FACS, Associate Professor of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of Nebraska Medical Center; Consulting Staff, Division of Head and Neck Surgical Oncology, Nebraska Methodist Hospital; Consulting Staff, Veterans Administration Medical Center, Omaha
Contributor Information and Disclosures

Updated: Aug 7, 2008

Introduction

Carcinoma of the buccal mucosa is relatively uncommon in North America, compared with other oral cavity cancers such as carcinomas of the tongue or floor of the mouth. Squamous cell carcinoma is the most common pathology and more prevalent in those who use tobacco and alcohol.

Problem

As the orifice of the upper aerodigestive tract, the oral cavity plays a critical role in breathing, speech, and swallowing. The buccal region is particularly important in bolus formation, preventing food from spilling into the lateral oral gutters or extraorally during the oral preparatory phase of swallowing. Cancer of the buccal mucosa and subsequent treatment of the disease may interfere with these functions.

Buccal carcinoma has the propensity to become aggressive, with high rates of locoregional recurrence.  Diagnosis and treatment at an early stage leads to significantly improved prognosis and function over advanced disease.

Frequency

Squamous cell carcinoma of the buccal mucosa accounts for 5-10% of all cancers of the oral cavity in North America and Western Europe. It occurs more often in men, with a male:female ratio of 3-4:1, and most commonly in the 7th or 8th decade of life.

The incidence of buccal carcinoma is much higher in Asia. In Southeast Asia, the disease is the most common form of oral cavity cancer. In India, buccal carcinoma is the most common cancer in men and the third most common cancer in women.  

The higher rate of buccal carcinoma in Asia is likely related to the widespread practice of betel nut chewing. Betel nut, composed mainly of the fruit of the Areca Palm and often mixed with tobacco, is placed along the buccal mucosa to induce a feeling of euphoria. Buccal carcinoma related to betel nut chewing tends to develop at an earlier age, with most cases occurring between the ages of 40-70.

Etiology

Tobacco and alcohol use are the main etiologic agents associated with the development of buccal carcinoma. In North America, a history of using tobacco is documented in 70% of patients. Although alcohol by itself is not thought to be a significant risk, tobacco and alcohol have a well-recognized synergistic effect in the development of carcinoma.

In Asia, betel nut is a significant etiologic agent, in addition to tobacco and alcohol.  In India, over 90% of patients with buccal carcinoma have a history of using betel nut.

Other suspected but not confirmed etiologic agents include human papilloma virus, poor oral hygiene, and chronic irritation.

Premalignant conditions include submucosal fibrosis and lichen planus. The latter has a reported transformation rate of 0.5-3%, whereas the former has a malignant transformation rate of 0.5%.

Presentation

Buccal carcinoma commonly presents as a slow-growing mass on the buccal mucosa. Small lesions tend to be asymptomatic and are often noted incidentally on dental examination. Pain commonly occurs as the lesion enlarges and ulceration develops. Oral intake may worsen the pain and lead to malnutrition and dehydration. Associated symptoms include bleeding, poor denture fit, facial weakness or sensory changes, dysphagia, odynophagia, and trismus.

A detailed medical history is important to determine the patient's candidacy for surgery or radiation therapy. The person often has a history of tobacco and alcohol use. A history of previous malignancies of the upper aerodigestive tract should be ascertained.

Comprehensive examination of the head and neck should be conducted with a focus on the oral cavity. The mucosa of all the subsites of the oral cavity and oropharynx should be examined systematically. Palpation is important to determine the depth of invasion. Mandibular or maxillary alveolar invasion should be noted on inspection and palpation. Dentition must also be assessed, especially if irradiation is part of the planned management. The larynx and hypopharynx should be assessed by means of examination with a mirror or flexible endoscopy to rule out a second primary tumor of the upper aerodigestive tract.

The ears should be examined in those patients with a history of otalgia because a lack of evidence of ear disease suggests referred pain due to malignancy.

The neck and parotid gland should be carefully examined for adenopathy. Diaz et al found that 27% of patients presented with clinically positive nodes.1 The risk of nodal disease at presentation increases with advanced-stage disease. A meta-analysis of 4 studies with 223 cases of buccal carcinoma by Chhetri et al found that most presented with T2 or T3 disease (12% T1, 47% T2, 19% T3, 22% T4).2 The rate of nodal metastases at presentation was 40% for T2 disease and 52% for T3 disease.

Signs of advanced disease on physical examination include bleeding, skin ulceration, facial swelling, neck mass, trismus, facial numbness, and paralysis of the facial musculature.

The lesion often has 1 of 3 morphologic types: exophytic, ulceroinfiltrative, or verrucous. The exophytic type is the most common, appearing as a papillary mass that becomes ulcerated when large. The ulceroinfiltrative variety appears as an ulcer that penetrates deep into the underlying structures, with surrounding induration. Verrucous carcinomas are uncommon variants of oral-cavity carcinomas; among these, the buccal mucosa is the most common site. These lesions appear as papillary masses, and keratinization gives them a whitish appearance.

Indications

Any lesion of the buccal mucosa suggestive of malignancy should be biopsied for pathologic diagnosis. Once a malignant diagnosis is established, treatment options include surgery, irradiation, or combined-modality therapy. Treatment recommendations should be based upon multiple factors, including the stage of the tumor, the patient's general health, and patient desires.

In North America, surgery is the primary treatment for buccal carcinoma. Adjuvant radiation or chemoradiation is offered based upon disease stage, as well as histopathologic factors. Primary radiation or chemoradiation is reserved for those patients who are poor surgical candidates.

In some parts of the world, nonsurgical therapy is considered the standard of care. In India, irradiation is the mainstay of treatment, with surgery and postoperative radiation therapy reserved for cases of advanced disease.

Relevant Anatomy

The American Joint Commission on Cancer defines the buccal mucosa as the membrane lining of the inner surface of the cheeks from the line of contact of the opposing lips anteriorly to the line of the pterygomandibular raphe (lateral to retromolar trigone) posteriorly. The medial boundary is the line of attachment of the buccal mucosa to the upper and lower alveolar ridges.

The layers of the cheek from medial to lateral include the mucosa, pharyngobasilar fascia, buccinator muscle, buccinator fat pad, subcutaneous tissue and skin. Sensory innervation of the buccal mucosa and cheek skin is from the maxillary and mandibular branches of the trigeminal nerve. The buccinator muscle is innervated by the facial nerve. The parotid duct (Stenson duct) pierces the buccinator muscle and buccal mucosa opposite the maxillary second molar.

The buccal region lacks anatomic barriers beyond the buccinator muscle and its fascia to prevent the spread of cancer. Buccal cancer can spread laterally to extend through the skin of the cheek; medially to involve the alveoli, palate, tongue, and floor of the mouth; posteriorly to involve the retromolar trigone mucosa, the ascending ramus of the mandible, and the masseter and pterygoid muscles; and anteriorly to involve the oral commissure and lips.

The primary-echelon lymphatics of the buccal mucosa drain to the facial and submandibular lymph node basins prior to the upper jugular nodes. The lymphatics may occasionally drain to the upper jugular nodes via the parotid nodes.

Contraindications

Contraindications to surgery include poor medical status, a patient's refusal of surgery, unresectable disease (eg, skull-base fixation and carotid encasement), and the presence of distant metastases.

Contraindications to radiation therapy include previous irradiation (relative contraindication) and collagen vascular disorders. Reluctance of the patient to undergo the dental intervention frequently required to prevent osteoradionecrosis is another relative contraindication for radiation therapy.

More on Buccal Carcinoma

Overview: Buccal Carcinoma
Workup: Buccal Carcinoma
Treatment: Buccal Carcinoma
Follow-up: Buccal Carcinoma
References

References

  1. Diaz EM Jr, Holsinger FC, Zuniga ER, et al. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. Head Neck. Apr 2003;25(4):267-73. [Medline].

  2. Chhetri DK, Rawnsley JD, Calcaterra TC. Carcinoma of the buccal mucosa. Otolaryngol Head Neck Surg. Nov 2000;123(5):566-71. [Medline].

  3. Bahadur S, Chatterjee TK. Chemotherapy in buccal mucosa cancer. J Surg Oncol. Aug 1986;32(4):245-7. [Medline].

  4. Bailey BJ, Calhoun KH. Head and Neck Surgery. 3rd ed. Philadelphia, PA: Lippincott-Raven; 2002.

  5. Cherian T, Sebastian P, Ahamed MI, et al. Evaluation of salvage surgery in heavily irradiated cancer of the buccal mucosa. Cancer. Jul 15 1991;68(2):295-9. [Medline].

  6. Cummings CW, Fredrickson JM, Harker LA, et al. Otolaryngology Head and Neck Surgery. 3rd ed. St. Louis: Mosby-Year Book; 1998.

  7. Fang FM, Leung SW, Huang CC, et al. Combined-modality therapy for squamous carcinoma of the buccal mucosa: treatment results and prognostic factors. Head Neck. Sep 1997;19(6):506-12. [Medline].

  8. Funk GF, Karnell LH, Robinson RA, et al. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck. Feb 2002;24(2):165-80. [Medline].

  9. Ildstad ST, Bigelow ME, Remensnyder JP. Clinical behavior and results of current therapeutic modalities for squamous cell carcinoma of the buccal mucosa. Surg Gynecol Obstet. Mar 1985;160(3):254-8. [Medline].

  10. McGuirt WF. Snuff dipper's carcinoma. Arch Otolaryngol. Nov 1983;109(11):757-60. [Medline].

  11. Mishra RC, Parida G, Mishra TK, Mohanty S. Tumour thickness and relationship to locoregional failure in cancer of the buccal mucosa. Eur J Surg Oncol. Apr 1999;25(2):186-9. [Medline].

  12. Mishra RC, Singh DN, Mishra TK. Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial. Eur J Surg Oncol. Oct 1996;22(5):502-4. [Medline].

  13. Nair MK, Sankaranarayanan R, Padmanabhan TK. Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa. Cancer. Apr 1 1988;61(7):1326-31. [Medline].

  14. Pop LA, Eijkenboom WM, de Boer MF, et al. Evaluation of treatment results of squamous cell carcinoma of the buccal mucosa. Int J Radiat Oncol Biol Phys. Feb 1989;16(2):483-7. [Medline].

  15. Rhys Evans PH, Montgomery PQ, Gullane PJ. Principles and Practice of Head and Neck Oncology. London: Martin Dunitz; 2003.

  16. Sieczka E, Datta R, Singh A, et al. Cancer of the buccal mucosa: are margins and T-stage accurate predictors of local control?. Am J Otolaryngol. Nov-Dec 2001;22(6):395-9. [Medline].

  17. Strome SE, To W, Strawderman M, et al. Squamous cell carcinoma of the buccal mucosa. Otolaryngol Head Neck Surg. Mar 1999;120(3):375-9. [Medline].

  18. Urist MM, O'Brien CJ, Soong SJ, et al. Squamous cell carcinoma of the buccal mucosa: analysis of prognostic factors. Am J Surg. Oct 1987;154(4):411-4. [Medline].

Further Reading

Keywords

buccal squamous cell carcinoma, buccal SCC, oral squamous cell carcinoma, oral SCC, buccal cancer, cheek cancer, cheek carcinoma, oral cancer, oral-cavity cancer, oral cavity cancer, oral carcinoma, oral-cavity carcinoma, oral-cavity carcinoma, mouth cancer, mouth carcinoma, snuff dipping, betel nuts, cigarette smoking, chewing tobacco, Paan

Contributor Information and Disclosures

Author

Christopher Klem, MD, Consulting Staff, Department of Otolaryngology-Head and Neck Surgery, Tripler Army Medical Center
Christopher Klem, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, and American Society for Reconstructive Microsurgery
Disclosure: Nothing to disclose.

Coauthor(s)

David P Goldstein, MD, FRCSC, Consulting Staff, Department of Otolaryngology, Division of Head and Neck Oncology and Microvascular Reconstructive Surgery, University Health Network, Toronto
David P Goldstein, MD, FRCSC is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, and Canadian Society of Otolaryngology-Head & Neck Surgery
Disclosure: Nothing to disclose.

Gerry F Funk, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Iowa
Gerry F Funk, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery and American Head and Neck Society
Disclosure: Nothing to disclose.

Russell B Smith, MD, FACS, Associate Professor of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of Nebraska Medical Center; Consulting Staff, Division of Head and Neck Surgical Oncology, Nebraska Methodist Hospital; Consulting Staff, Veterans Administration Medical Center, Omaha
Russell B Smith, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, Iowa Medical Society, and Nebraska Medical Association
Disclosure: Arthrocare Consulting fee Consulting

Medical Editor

Benoit J Gosselin, MD, FRCSC, Associate Professor of Surgery, Dartmouth Medical School; Director, Comprehensive Head and Neck Oncology Program, Norris Cotton Cancer Center; Staff Otolaryngologist, Division of Otolaryngology-Head and Neck Surgery, Dartmouth-Hitchcock Medical Center
Benoit J Gosselin, MD, FRCSC is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Medical Association, American Rhinologic Society, Canadian Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery, College of Physicians and Surgeons of Ontario, New Hampshire Medical Society, North American Skull Base Society, and Ontario Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Karen Hall Calhoun, MD, William E Davis Professor and Chair, Department of Otolaryngology-Head and Neck Surgery, University of Missouri
Karen Hall Calhoun, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Rhinologic Society, Association for Research in Otolaryngology, Society of University Otolaryngologists-Head and Neck Surgeons, Southern Medical Association, Texas Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.